In a previous study, we evaluated the safety of biological drugs in the treatment of moderate to severe psoriasis \[[@CR1]\] and we found a quite favourable profile for these agents (adalimumab, ustekinumab and etanercept). More recently, a systematic review \[[@CR2]\] has found an increase in the incidence of serious infections in patients with rheumatoid arthritis treated with biological agents. To re-evaluate this issue, we carried out an updated analysis (Analysis 1) in which we included the data of the most recently approved agent for this indication (i.e. secukinumab). Furthermore, we performed a Bayesian meta-regression analysis (Analysis 2; temporal trend analysis) to investigate whether the incidence of infections has undergone any changes from 2000 to 2015.

Our updated literature search, based on PubMed, covered the previous 15 years and included only randomized controlled trials (see also Fig. S1 in the Supplementary Material and the PRISMA schematic of our search). In comparison with the search carried out for our previous study, the main difference was that secukinumab was also included among the agents evaluated for safety. In Analysis 1, we employed the same Bayesian network meta-analysis \[[@CR3]--[@CR5]\] as in our previous report, but the outcome measure was the odds ratio (rather than the risk difference) because in this way our results were comparable to those published by Singh et al. \[[@CR2]\]. In Analysis 2, we employed a meta-regression model based on the same Bayesian approach \[[@CR6]\], in which the covariate (calendar year) was handled as a continuous variable. All the Bayesian models adopted for our analyses \[[@CR3]--[@CR6]\] have been developed by the National Institute for Health and Care Excellence Support Unit (UK) and are available as a fixed-effects model and a random-effects model. In both analyses, we employed the random-effects model (which is more conservative) because we anticipated the presence of heterogeneity. All statistical calculations were performed using the software package WinBUGS 1.4.3 (Cambridge, UK).

Our literature search extracted a total of 121 eligible citations. We excluded 95 citations on the basis of the abstract or the title. We then examined the full text of the remaining 26 articles and we finally selected a total of 13 randomized controlled trials that met our inclusion criteria. Of these 13 studies, two evaluated adalimumab, five ustekinumab (45 and 90 mg), four low- and high-dose etanercept and two secukinumab (150 and 300 mg). All of these trials adopted a double-blind design and analysed the safety of these treatments in terms of any infectious adverse event. Table [1](#Tab1){ref-type="table"} illustrates the raw data of infection incidence, extracted from these 13 trials.Table 1Incidence of any infectious adverse event in 13 randomized trials^a^Study no.First author or trial acronym (year of publication)Any infectious adverse eventTotal no. of patientsTreatmentFollow-up1Menter et al. (2008)89398PlaceboAt week 161Menter et al. (2008)235814Adalimumab2Asahina et al. (2010)2346PlaceboAt week 242Asashina et al. (2010)1843Adalimumab3Papp et al. (2008)82410PlaceboAt week 123Papp et al. (2008)88409Ustekinumab 45 mg3Papp et al. (2008)92411Ustekinumab 90 mg4Igarashi et al. (2012)632PlaceboAt week 124Igarashi et al. (2012)1364Ustekinumab 45 mg4Igarashi et al. (2012)1562Ustekinumab 90 mg5Leonardi et al. (2008)68255PlaceboAt week 125Leonardi et al. (2008)80255Ustekinumab 45 mg5Leonardi et al. (2008)66255Ustekinumab 90 mg6Tsai et al. (2011)1460PlaceboAt week 126Tsai et al. (2011)2061Ustekinumab 45 mg7Zhu et al. (2013)31161PlaceboAt week 127Zhu et al. (2013)41160Ustekinumab 45 mg8Tyring et al. (2006)71306PlaceboAt week 128Tyring et al. (2006)87312HDE9Papp et al. (2005)25193PlaceboAt week 129Papp et al. (2005)26196LDE9Papp et al. (2005)75194HDE10Leonardi et al. (2003)19166PlaceboAt week 1210Leonardi et al. (2003)16160LDE10Leonardi et al. (2003)9164HDE11Van de Kerkhof et al. (2008)1246PlaceboAt week 2411Van de Kerkhof et al. (2003)1796HDE12FIXTURE (2014)163327PlaceboAt week 1212FIXTURE (2014)101327Secukinumab 150 mg12FIXTURE (2014)87326Secukinumab 300 mg13ERASURE (2014)40248PlaceboAt week 1213ERASURE (2014)66245Secukinumab 150 mg13ERASURE (2014)72245Secukinumab 300 mg*HDE* high-dose etanercept, *LDE* low-dose etanercept^a^Table S1 in the Supplementary Material provides the full bibliographic details of the 13 trials included in our analysis

Figure [1](#Fig1){ref-type="fig"} shows the results of Analysis 1 focused on the incidence of any infectious adverse event. The analysis generated seven direct comparisons between an active agent (adalimumab, ustekinumab 45 mg, ustekinumab 90 mg, high-dose etanercept, low-dose etanercept, secukinumab 150 mg or secukinumab 300 mg) and placebo and 17 indirect comparisons between the active agents in all possible combinations. Because all the indirect comparisons were little informative, Fig. [1](#Fig1){ref-type="fig"} has been restricted to the direct comparisons, which however were very far from demonstrating any difference. Analysis 2 (temporal trend analysis) found a regression coefficient close to 0 (value: +0.0336; 95 % credible interval −0.219 to 0.283); this result identifies a flat (i.e. approximately horizontal) meta-regression line that fails to suggest any effect of time on the risk of infection related to biologic drugs. Because the risk of infection is not likely to depend on the patients' disease condition (rheumatoid arthritis or psoriasis), further studies are needed to shed light on this controversial issue.Fig. 1Endpoint of any infectious adverse event. Forest plot of the values of odds ratios (with 95 % credible intervals) calculated for seven direct comparisons of active agents vs. controls according to the Bayesian random-effects model. *ADA* adalimumab, *U45* ustekinumab 45 mg, *U90* ustekinumab 90 mg, *HDE* high-dose etanercept, *LDE* low-dose etanercept, *SEC150* secukinumab 150 mg, *SEC300* secukinumab 300 mg

In conclusion, our results provided a synthesis of the information currently available from randomized trials concerning the risk of infections attributable to biological agents in patients with moderate to severe psoriasis. All biological agents currently approved in Europe were tested. Interestingly enough, while in their study on rheumatoid arthritis Singh et al. \[[@CR2]\] found a significantly increased risk of infections in the direct comparisons between biological agents and controls, our results from patients with psoriasis did not suggest any such conclusion.
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